Patents by Inventor Caterina Bissantz
Caterina Bissantz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10385022Abstract: This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.Type: GrantFiled: February 6, 2015Date of Patent: August 20, 2019Assignee: HOFFMANN-LA ROCHE INC.Inventors: Caterina Bissantz, Henrietta Dehmlow, Shawn David Erickson, Prabha Saba Karnachi, Kyungjin Kim, Rainer E. Martin, Patrizio Mattei, Ulrike Obst Sander, Sherrie Lynn Pietranico-Cole, Hans Richter, Christoph Ullmer
-
Patent number: 9957298Abstract: The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.Type: GrantFiled: December 2, 2016Date of Patent: May 1, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Konrad Bleicher, Christophe Grundschober
-
Patent number: 9868766Abstract: The invention relates to compounds of formula wherein variables are defined herein. It has been found that the present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrom.Type: GrantFiled: June 18, 2015Date of Patent: January 16, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Caterina Bissantz, Konrad Bleicher, Christophe Grundschober
-
Patent number: 9751870Abstract: The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen or cycloalkyl; A2 is phenyl; R2 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, S-lower alkyl substituted by halogen, S(O)2-lower alkyl substituted by halogen; n is 1 or 2; or a pharmaceutically acceptable acid addition salt, or a racemic mixture or its corresponding enantiomer and/or optical isomers thereof, for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.Type: GrantFiled: July 17, 2015Date of Patent: September 5, 2017Assignee: HOFFMAN-LA ROCHE INC.Inventors: Caterina Bissantz, Christophe Grundschober, Matthias Nettekoven, Jean-Marc Plancher, Walter Vifian
-
Patent number: 9656971Abstract: The present invention relates to compounds of formula wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.Type: GrantFiled: June 26, 2015Date of Patent: May 23, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, René Bonnafous, Bernd Buettelmann, Roland Jakob-Roetne, Christian Lerner, Markus Rudolph
-
Publication number: 20170081368Abstract: The present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post-traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.Type: ApplicationFiled: December 5, 2016Publication date: March 23, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Konrad Bleicher, Kanchan Chakraborty, Christophe Grundschober, Goutam Saha
-
Publication number: 20170081369Abstract: The present compounds compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.Type: ApplicationFiled: December 2, 2016Publication date: March 23, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Konrad Bleichcher, Christophe Grundschober
-
Patent number: 9403808Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament. In particular, the compound may be used as a preferential agonist of Cannabinoid Receptor 2.Type: GrantFiled: October 24, 2012Date of Patent: August 2, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Baledi Dhurwasulu, Uwe Grether, Anindya Hazra, Paul Hebeisen, Stephan Roever, Mark Rogers-Evans
-
Publication number: 20160137606Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: January 21, 2016Publication date: May 19, 2016Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
-
Patent number: 9321727Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.Type: GrantFiled: June 1, 2012Date of Patent: April 26, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
-
Patent number: 9290451Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.Type: GrantFiled: June 1, 2012Date of Patent: March 22, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
-
Publication number: 20160002177Abstract: The present invention relates to compounds of formula wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.Type: ApplicationFiled: June 26, 2015Publication date: January 7, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Caterina BISSANTZ, René Bonnafous, Bernd Buettelmann, Roland Jakob-Roetne, Christian Lerner, Markus Rudolph
-
Publication number: 20150322058Abstract: The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen or cycloalkyl; A2 is phenyl; R2 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, S-lower alkyl substituted by halogen, S(O)2-lower alkyl substituted by halogen; n is 1 or 2; or a pharmaceutically acceptable acid addition salt, or a racemic mixture or its corresponding enantiomer and/or optical isomers thereof, for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.Type: ApplicationFiled: July 17, 2015Publication date: November 12, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Caterina Bissantz, Christophe Grundschober, Matthias Nettekoven, Jean-Marc Plancher, Walter Vifian
-
Publication number: 20150284434Abstract: The invention relates to compounds of formula wherein variables are defined herein. It has been found that the present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrom.Type: ApplicationFiled: June 18, 2015Publication date: October 8, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Caterina Bissantz, Konrad Bleicher, Christophe Grundschober
-
Patent number: 9067943Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: GrantFiled: November 19, 2012Date of Patent: June 30, 2015Assignee: HOFFMANN-LA ROCHE INC.Inventors: Caterina Bissantz, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
-
Patent number: 9056866Abstract: The invention relates to a compound of formula (I) wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: GrantFiled: April 11, 2014Date of Patent: June 16, 2015Assignee: Hoffmann-La Roche Inc.Inventors: Jean-Michel Adam, Caterina Bissantz, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
-
Publication number: 20150152058Abstract: This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.Type: ApplicationFiled: February 6, 2015Publication date: June 4, 2015Inventors: Caterina Bissantz, Henrietta Dehmlow, Shawn David Erickson, Prabha Saba Karnachi, Kyungjin Kim, Rainer E. Martin, Patrizio Mattei, Ulrike Obst Sander, Sherrie Lynn Pietranico-Cole, Hans Richter, Christoph Ullmer
-
Patent number: 8987307Abstract: This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.Type: GrantFiled: February 28, 2012Date of Patent: March 24, 2015Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Henrietta Dehmlow, Shawn David Erickson, Prabha Saba Karnachi, Kyungjin Kim, Rainer E. Martin, Patrizio Mattei, Ulrike Obst Sander, Sherrie Lynn Pietranico-Cole, Hans Richter, Christoph Ullmer
-
Publication number: 20140288046Abstract: The invention relates to a compound of formula (I) wherein A, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: April 11, 2014Publication date: September 25, 2014Applicant: HOFFMANN-LA ROCHE INC.Inventors: Jean-Michel Adam, Caterina Bissantz, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
-
Patent number: 8765730Abstract: This invention relates to novel 1-hydroxyimino-3-phenyl-propanes of the formula wherein R1 to R10 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may be used as medicaments for the treatment of diseases such as type II diabetes.Type: GrantFiled: July 12, 2011Date of Patent: July 1, 2014Assignee: Hoffmann-La Roche IncInventors: Caterina Bissantz, Henrietta Dehmlow, Shawn David Erickson, Kyungjin Kim, Rainer E. Martin, Patrizio Mattei, Ulrike Obst Sander, Sherrie Lynn Pietranico-Cole, Hans Richter, Christoph Ullmer